Also known as Edurant
Rilpivirine (TMC278, trade name Edurant) is a pharmaceutical drug, developed by Tibotec, for the treatment of HIV infection. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz.
Source: WikipediaPatients are most commonly prescribed rilpivirine to treat rabies, blastomycosis, west nile virus, and pick disease.
Critical Interactions
Significant Interactions